Our colorectal trial ... LB-100 compound with various innovative cancer immunotherapies. Completion of a registered direct offering, raising aggregate gross proceeds of approximately $1,050,000 ...

The “scary thing” turned out to be her reality: stage 3 colon cancer, and time was critical. Had her tumor spread just a millimeter deeper into her colon wall during the time she was seeking a ...

A study published April 14 by JAMA Network Open found that rates of pancreatic and colon cancer rose among young adults from ...

A recent study published in the American Journal of Gastroenterology investigates the incidence and survival rates of ...

There has been a sharp increase in colorectal and pancreatic cancer rates among Americans under 55 years, despite declines in older adults, according to a new study.

Colon cancer is one of the most common cancers in the United States and cases among younger adults are rising. Early detection is critical, as symptoms may not appear until the cancer has progressed.

The American Cancer Society recommends people at average risk of colorectal cancer start screening at age 45, now several blood tests could help.

Colorectal cancer stands as the third leading cause of cancer-related deaths in US men and the fourth leading cause in US women, according to the American Cancer Society. This year, over 150,000 ...

"I don't think anything can prepare you for that moment when you're told you have cancer," she said. Brinlee Luster was diagnosed with stage IV colon cancer and underwent 30 rounds of chemotherapy ...

Detailed price information for Lixte Biotech Hlds (LIXT-Q) from The Globe and Mail including charting and trades.